Rein Therapeutics (015A) Financial Statements
Rein Therapeutics Financial Overview
Rein Therapeutics's market cap is currently $51.58M. The company's EPS TTM is $-1.83; its P/E ratio is -0.37; Rein Therapeutics is estimated to report earnings on November 6, 2026, and the estimated EPS forecast is $-0.09. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -1.00K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -21.93M | $ -65.11M | $ -16.28K | $ -27.65K | $ -26.61K |
| EBITDA | $ -50.58M | $ -28.05M | $ 103.65K | $ 141.67K | $ 94.84K |
| Net Income | $ -49.87M | $ -62.88M | $ -15.73K | $ -27.33K | $ -26.16K |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.21M | $ 12.87M | $ 17.31M | $ 21.24M | $ 45.93M |
| Total Assets | $ 24.16M | $ 69.24M | $ 106.01M | $ 22.01M | $ 48.48M |
| Total Debt | $ 0.00 | $ 0.00 | $ 48.00K | $ 33.00K | $ 162.00K |
| Net Debt | $ -3.21M | $ -12.87M | $ -17.27M | $ -5.16M | $ -3.44M |
| Total Liabilities | $ 7.24M | $ 14.85M | $ 99.12M | $ 3.38M | $ 4.58M |
| Stockholders' Equity | $ 16.92M | $ 54.39M | $ 6.89M | $ 18.62M | $ 43.90M |
| Cash Flow | |||||
| Free Cash Flow | $ -19.36M | $ -22.29M | $ -19.81M | $ -24.86M | $ -23.91M |
| Operating Cash Flow | $ -19.36M | $ -22.29M | $ -19.81M | $ -24.86M | $ -23.75M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 16.20M | $ 26.46M | $ -35.92M |
| Financing Cash Flow | $ 9.76M | $ 17.82M | $ 15.79M | $ 0.00 | $ 55.66M |
Currency in USD